

**INFORMATION OF SOPHARMA AD ON FACTS
AND CIRCUMSTANCES WHICH HAVE OCCURRED
AS AT 2019
OF SOPHARMA AD**

- 1.1. No change in the persons controlling the Company.
- 1.2. (Annulled – State Gazette, issue 63 from 2016).
- 1.3. (Annulled – State Gazette, issue 63 from 2016).
- 1.4. (Annulled – State Gazette, issue 63 from 2016).
- 1.5. (Annulled – State Gazette, issue 63 from 2016).
- 1.6. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.
- 1.7. No acquisition, use or disposition of high-value assets.
- 1.8. No decision on conclusion, termination and cancellation of joint venture agreements.
- 1.9. (Annulled – State Gazette, issue 82 from 2007).
- 1.10. Change of the Company's Auditors - At the Annual General Meeting of Shareholders of SOPHARMA AD, held on 7 June 2019, the auditor company "BAYKER TILLY KLITOU AND PARTNERS" AD, with headquarters in Sofia, Acad. Ivan Evst. Geshov "№ 104, was elected for the auditing and certifying of the Annual Financial Statement of the Company for 2018.
- 1.11. (Annulled – State Gazette, issue 63 from 2016).
- 1.12. (Annulled – State Gazette, issue 63 from 2016).
- 1.13. (Annulled – State Gazette, issue 63 from 2016).
- 1.14. (Annulled – State Gazette, issue 63 from 2016).
- 1.15. (Annulled – State Gazette, issue 63 from 2016).
- 1.16. (Annulled – State Gazette, issue 63 from 2016).
- 1.17. (Annulled – State Gazette, issue 63 from 2016).
- 1.18. (Annulled – State Gazette, issue 63 from 2016).
- 1.19. (Annulled – State Gazette, issue 63 from 2016).
- 1.20. (Annulled – State Gazette, issue 63 from 2016).
- 1.21. (Annulled – State Gazette, issue 63 from 2016) No conclusion or performance of essential contracts, which do not relate to the ordinary business of the Company.
- 1.22. (Annulled – State Gazette, issue 63 from 2016).
- 1.23. (Annulled – State Gazette, issue 63 from 2016).
- 1.24. (Annulled – State Gazette, issue 63 from 2016).
- 1.25. (Annulled – State Gazette, issue 63 from 2016).
- 1.26. (Annulled – State Gazette, issue 63 from 2016).
- 1.27. (Annulled – State Gazette, issue 63 from 2016).
- 1.28. (Annulled – State Gazette, issue 63 from 2016).

1.29. (Annulled – State Gazette, issue 63 from 2016).

1.30. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10% of the company's equity.

1.31. Purchase, sale or pledge of shareholdings in companies by the issuer or its subsidiary.

On 15.01.2019 an agreement was signed for the acquisition of the non-controlling interest of the subsidiary Sopharma Trading AD in the capital of Lekovit O.O. at the rate of 30%. After the performance of the contract, on 04.02.2019 100% ownership of the capital was registered by the subsidiary Sopharma Trading AD.

On 02.01.2019 the merger of OO Med-dend, Belarus with BOOO Special Airfarmation, Belarus was registered by merging the assets and liabilities of the two companies. The activity of the merged company OOO Meddend is terminated and all its rights and obligations at the moment of the merger are taken by BOOO Special Airfarmation, Belarus.

On 15.02.2019 a deal was made for the disposal by Sopharma AD of 253,000 shares of the capital of Momina Krepost AD, with which the share of Sopharma AD in the capital of Momina Krepost AD falls from 93.56% to 78.60%.

On 07.03.2019 through its subsidiary SOOO Britetrade, Belarus, the Group acquired a 25% stake in OSB Bellerofon, Belarus, as a result of which the parent acquires control and the company is classified as a subsidiary.

As at 29.03.2019 after the sale of 126,626 shares of the capital of Momina Krepost AD, the share of Sopharma AD in the capital of Momina Krepost AD went below 75% - from 78.60% (1 329 212 shares) to 71.11% (1 202 590 shares).

As at 12.09.2019 after the sale of 94 636 shares of the capital of Momina Krepost AD, the share of Sopharma AD in the capital of Momina Krepost AD passes the threshold from 70% to 65.07% (1 100 398 shares).

As at 02.12.2019 after the sale of 32 500 shares of the capital of Momina Krepost AD, the share of Sopharma AD in the capital of Momina Krepost AD passes the threshold from 65% to 63.12% (1 067 398 shares).

1.32. (Annulled – State Gazette, issue 63 from 2016).

1.33. (Annulled – State Gazette, issue 63 from 2016).

1.34. Other circumstances that the Company considers may be relevant to investors in taking a decision to acquire, sell or continue to hold publicly-traded securities: none.

Sopharma AD informs all interested parties that the interim financial statements of the Company as at 31 December 2019 have not been verified by a registered auditor.

Ognian Donev
Executive director

